Renowned global builder of boards and executive teams aligns with leading women’s health innovator, signaling next phase of commercial growth
Mammogen, a women-built and women-led predictive health company redefining what’s possible in early disease detection, announced the appointment of Denise “DeeDee” DeMan as Chairwoman of its Board of Directors.
Health Technology Insights: Biogen Shares New Nusinersen Data to Advance SMA Outcomes
DeMan, Founder, Chair, and CEO of Bench International, is one of the most respected leadership architects in global life sciences. With more than five decades of experience placing board directors, chairpersons, and C-level executives for some of the world’s most successful and enduring healthcare companies, DeMan has built the leadership teams behind healthcare’s most transformative innovations and industry-defining growth stories. Through initiatives such as Bench’s acclaimed Bank of Women, DeMan has helped organizations unlock the power of inclusive governance and executive excellence, aligning with Mammogen’s commitment to having women’s voices represented at every level of the company.
Her appointment reflects Mammogen’s evolution from a research-stage innovator to a clinical-stage company preparing for commercialization, as it advances its blood-based early detection test for breast cancer towards market launch.
Health Technology Insights: Mindful Lemon Partners with Qualifacts to Boost LA Care
Mammogen’s flagship product, genTRU, is designed to detect breast cancer at its earliest and most treatable stages, focusing on quality-of-life preservation. The genTRU assay has demonstrated over 99% sensitivity and 89% specificity for Stage I disease, supported by several peer-reviewed publications and extensive clinical validation.
“Mammogen combines validated science, disciplined execution, and purpose-driven leadership—qualities that define the companies that change clinical landscapes and build commercial titans,” said DeMan. “I’ve spent my career guiding organizations from inflection to impact, and it’s rare to see this level of readiness and rigor at such a formative stage. I’m honored to serve as Chairwoman as we guide Mammogen into its next era of growth, and I’m committed to ensuring its leadership and governance are as differentiated as its science.”
With pivotal trials underway, the company is preparing for commercialization as the world’s first and most accurate targeted screening test for breast cancer, addressing an urgent unmet need for over 25 million U.S. women currently at-risk based on Mammography Quality Standards Act (MQSA) Guidelines.
“DeeDee’s decision to join Mammogen at this critical juncture sends a clear message: we are building for scale, staying true to science, and ready to deliver paradigm-shifting value at a time when the market is demanding exactly that,” said Elizabeth Cormier-May, CEO of Mammogen. “Her expertise in building governance and leadership for companies that endure is invaluable as we prepare for what’s next.”
As Chairwoman, DeMan will lead Mammogen’s board governance strategy and support the company in strengthening its industry position as it accelerates towards this next stage of growth.
Health Technology Insights: Study: Virtual MSK Care Boosts Outcomes for Medicare Members
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Web
